Norfloxacin for prevention of bacterial infections during severe granulocytopenia after bone marrow transplantation.
48 patients treated with bone marrow transplantation (BMT) received the quinolone norfloxacin (NOR) in a total decontamination (TD-NOR, n = 36) or selective decontamination (SD-NOR, n = 12) regimen and were compared with a historical control group of 48 BMT patients receiving oral non-absorbable antibiotics (TD-NAA, n = 31 and SD-NAA, n = 17). 17/36 patients (47%) of group TD-NOR and 16/31 patients (52%) of group TD-NAA remained free of febrile episodes and infections. 4/12 patients (33%) of group SD-NOR and only 1/17 patients (6%) of group SD-NAA remained free of fever and infections. The use of norfloxacin in selective decontamination resulted in a statistically significant lower incidence of fever days than in patients receiving SD-NAA (p less than 0.001). These data suggest that norfloxacin may replace non-absorbable antibiotics in total and in selective decontamination regimens used for infection prophylaxis in BMT recipients.
Schmeiser
T
T
Department of Internal Medicine, University of Ulm, FRG.
Kurrle
E
E
Arnold
R
R
Wiesneth
M
M
Bunjes
D
D
Hertenstein
B
B
Kern
W
W
Heit
W
W
Heimpel
H
H
D000293:Adolescent; D000328:Adult; D000380:Agranulocytosis / Q000150:complications*; D001424:Bacterial Infections / Q000517:prevention & control*; D016026:Bone Marrow Transplantation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009643:Norfloxacin / Q000627:therapeutic use*; D018805:Sepsis / Q000517:prevention & control; D013203:Staphylococcal Infections / Q000517:prevention & control; D013290:Streptococcal Infections / Q000517:prevention & control; D013997:Time Factors
D009643:Norfloxacin